Fawzy A, et al. - Researchers determined the impact of aspirin on COPD morbidity among participants with COPD (FEV₁/FVC < 70%) of the SPIROMICS trial. Baseline self-reported daily aspirin use was evaluated. Quarterly structured telephone questionnaires were used up to 3 years to prospectively ascertain acute exacerbations of COPD (AECOPD), categorized as moderate (symptoms treated with antibiotics or oral corticosteroids) or severe (requiring emergency department visit or hospitalization). Using propensity score matching, the investigators matched aspirin users one-to-one with nonusers, resulting in 503 participant pairs. They used zero-inflated negative binomial models to determine the association of aspirin use with total, moderate, and severe AECOPD. They also determined the association with baseline respiratory symptoms, quality of life, and exercise tolerance by using linear or logistic regression. This analysis included 1,698 participants. At baseline, daily aspirin use was reported by 45% participants. According to findings, reduced rate of COPD exacerbations, less dyspnea, and better quality of life were observed in association with daily aspirin use.